Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 1/20 | 0.76 |
| ▸ | BLM | P54132 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentylenetetrazol SCHEMBL9838533 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MEN1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL6407957 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL3182039 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MEN1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL22674 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MEN1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL10408117 | 0.85 | ALDH1A1 (0.96) | ALDH1A1MEN1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL28442995 | 0.85 | ALDH1A1 (0.96) | ALDH1A1MEN1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL15057132 | 0.85 | ALDH1A1 (0.96) | ALDH1A1MEN1MAPTBLMKMT2A | |
| Pentylenetetrazol SCHEMBL10873243 | 0.85 | ALDH1A1 (0.96) | ALDH1A1MEN1MAPTBLMKMT2A | |
| SCHEMBL2211329 | 0.85 | — | — | |
| Pentylenetetrazol SCHEMBL28326199 | 0.82 | ALDH1A1 (0.88) | ALDH1A1MEN1MAPTBLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112566986-A | Silicon-substituted rhodamine dyes and dye conjugates | 生命技术公司 | 2021-03-26 | — | — | CN | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | SANKYO COMPANY, LIMITED (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1568704-A1 | NOVEL 2' ,5' -OLIGOADENYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2005-08-31 | — | — | EP | disclosed |
| WO-2002055535-A2 | ANTISENSE MODULATION OF CYTOHESIN-1 EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261235-A1 | 2' ,5' -Oligoadenylate analogs | NSUN2, RNGTT, NSUN3 | ALDH1A1 820/4885MEN1 2377/4885MAPT 4767/4885 |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | ALDH1A1 3261/4885MEN1 2073/4885MAPT 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.